SCHEMBL14294757

SCHEMBL14294757

C[C@@H](C(=O)OCCN1C(=O)CCC(N2C(=O)c3cccc(F)c3C2=O)C1=O)N(C)C

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 13/20 0.44
CRBN Q96SW2 13/20 0.44
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
MAP1LC3B Q9GZQ8 1/20 0.34
CHRM3 P20309 1/20 0.33
TNF P01375 1/20 0.32
IL1B P01584 1/20 0.32
TBXA2R P21731 1/20 0.32
IKZF1 Q13422 1/20 0.32
IKZF3 Q9UKT9 1/20 0.32
STAT3 P40763 1/20 0.32
TRPA1 O75762 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14294750 0.91 DDB1 (0.43) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL14294756 0.91 DDB1 (0.43) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL14294746 0.90 DDB1 (0.43) DDB1CRBNMAP1LC3BTNFIL1B
SCHEMBL14294758 0.89 DDB1 (0.45) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL14294752 0.88 DDB1 (0.44) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL14294762 0.88 DDB1 (0.44) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL4936599 0.87 DDB1 (0.48) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL4938214 0.87 DDB1 (0.47) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL14294760 0.86 DDB1 (0.41) DDB1CRBNADRA1DADRA1AADRA1B
SCHEMBL14294738 0.86 DDB1 (0.43) DDB1CRBNADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-09-10 US disclosed
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2019-08-15 US disclosed
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-01-01 US disclosed
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2018-02-22 US disclosed
US-8637545-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-01-28 US disclosed
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNFRSF9, TNFRSF1A, NGFR DDB1 2855/4885CRBN 949/4885ADRA1D 199/4885
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNF, TNFRSF1A, TNFRSF9 DDB1 2336/4885CRBN 896/4885ADRA1D 248/4885
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNFRSF1A, TNFRSF9, NGFR DDB1 2770/4885CRBN 1007/4885ADRA1D 190/4885
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DDB1 2373/4885CRBN 862/4885ADRA1D 284/4885
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DDB1 2336/4885CRBN 896/4885ADRA1D 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.